SNP309 polymorphism in the MDM2 gene in evaluation of chronic lymphocytic leukemia outcome in combination with other prognostic markers
Kriachok I.A.1, Martіna Z.V. 2, Dyagil I.S.2
- 1National Cancer Institute, Kyiv
- 2SE «National Research Center of Radiation Medicine, National Academy of Medical Sciences of Ukraine», Kyiv
Summary. To define the value of MDM2 SNP309 polymorphism for the assessment of clinical characteristics and outcome of chronic lymphocytic leukemia (CLL). MDM2 SNP309 polymorphism was studied in 224 CLL patients by polymerase chain reaction with restriction fragment length polymorphism analysis and correlated with other prognostic factors (age at diagnosis, initial leukocytosis, stage at diagnosis, mutational status of immunoglobulin heavy chain variable region (IGHV) genes, presence of mutations in the TP53 gene). Analysis of the entire group of patients showed no influence of SNP309 polymorphism on clinical data at diagnosis, the development of secondary complications and survival rates when other prognostic factors where considered. However, the association of the SNP309 GG genotype with faster progression (р=0,013) and shorter overall survival (р=0,014) was seen in the subgroup of patients with no mutations in the TP53 gene and unmutated IGHV genes. The assessment of MDM2 SNP309 polymorohism may be used as additional prognostic marker in CLL.
Leave a comment